Phosphorylated self-peptides alter human leukocyte antigen class l-restricted antigen presentation and generate tumor-specific epitopes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 8, 2009, Pages 2776-2781

  Petersen, Jan ^a   Wurzbacher, Stephanie J ^b   Williamson, Nicholas A ^b   Ramarathinam, Sri H ^b   Reid, Hugh H ^a   Nair, Ashish K N ^b   Zhao, Anne Y ^b   Nastovska, Roza ^b   Rudge, Geordie ^b   Rossjohn, Jamie ^a   Purcell, Anthony W ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antigen presentation; HLA; Phosphopeptide; T cells x ray crystallography

Indexed keywords

BETA CATENIN; CELL CYCLE PROTEIN 25B; HLA A2 ANTIGEN; INSULIN RECEPTOR SUBSTRATE 2; PHOSPHOAMINO ACID; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG STRUCTURE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; PEPTIDES; PHOSPHORYLATION; PROTEIN CONFORMATION;

EID: 62449239575     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812901106     Document Type: Article

References (25)

1. Johnson DA (2008) Synthetic TLR4-active glycolipids as vaccine adjuvants and standalone immunotherapeutics. Curr Top Med Chem 8:64-79.
2. Dorn A, Kippenberger S (2008) Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as irnmunomodulators. Curr Opin Mol Ther 10:10-20.
3. Morita CT, Jin C, Sarikonda G, Wang H (2007) Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: Discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 215:59-76.
4. Betser-Cohen G, et al. (2006) Reduced KIR2DL1 recognition of MHC class I molecules presenting phosphorylated peptides. J Immunol 176:6762-6769.
5. Mandell JW (2003) Phosphorylation state-specific antibodies: Applications in investigative and diagnostic pathology. Am J Pathol 163:1687-1698.
6. Datta SK (2003) Major peptide autoepitopes for nucleosome-centered T and B cell interaction in human and murine lupus. Ann N Y Acad Sci 987:79-90.
7. Utz PJ, Hottelet M, van Venrooij WJ, Anderson P (1998) Association of phosphorylated serine/arginine (SR) splicing factors with the Ul-small ribonucleoprotein (snRNP) au- toantigen complex accompanies apoptotic cell death. J Exp Med 187:547-560.
8. Zarling AL, et al. (2000) Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 192:1755-1762.
9. Zarling AL, et al. (2006) Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci USA 103:14889-14894.
10. Andersen MH, et al. (1999) Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide- specific CTL. J Immunol 163:3812-3818.
11. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev 188:22-32.
12. Mayordomo J I, et al. (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183:1357-1365.
13. Williamson NA, Rossjohn J, Purcell AW (2006) Tumors reveal their secrets to cytotoxic T cells. Proc Natl Acad Sci USA 103:14649-14650.
14. Gottschalk S, Heslop HE, Rooney CM (2005) Adoptive immunotherapy for EBV- associated malignancies. Leuk Lymphoma 46:1-10.
15. Mohammed F, et al. (2008) Phosphorylation-dependent interaction between antigenic peptides and MHC class I: A molecular basis for the presentation of transformed self. Nat Immunol 9:1236-1243.
16. Tynan FE, et al. (2005) Tcell receptor recognition of a 'super-bulged' major histocompatibility complex class l-bound peptide. Nat Immunol 6:1114-1122.
17. Webb Al, et al. (2004) Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue. J Biol Chem 279:23438-23446.
18. Storoni LC, McCoy AJ, Read RJ (2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D 60(Pt 3):432-438.
19. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D 53(Pt 3):240-255.
20. Adams PD, et al. (2002) PHENIX: Building new software for automated crystal lographic structure determination. Acta Crystallogr D 58:1948-1954.
21. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D 60(Pt 1):2126-2132.
22. Baker NA, Sept D, Josephs, Hoist MJ, McCammon JA (2001) Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc Natl Acad Sci USA 98:10037-10041.
23. van der Burg SH, et al. (1995) An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells: Identification of conserved HIV-1 polymerase peptides binding to HLA-A *0301. Human Immunol 44:189-198.
24. Purcell AW, et al. (2001) Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J Immunol 166:1016-1027.
25. Garboczi DN, et al. (1996) Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134-141.